Prognostic value of serum oncomarkers for patients hospitalized with acute exacerbation of interstitial lung disease
- PMID: 38757948
- PMCID: PMC11102678
- DOI: 10.1177/17534666241250332
Prognostic value of serum oncomarkers for patients hospitalized with acute exacerbation of interstitial lung disease
Abstract
Background: Different types of inflammatory processes and fibrosis have been implicated in the pathogenesis of interstitial lung disease (ILD), a heterogeneous, diffuse, parenchymal lung disease. Acute exacerbation (AE) of ILD is characterized by significant respiratory deterioration and is associated with high mortality rates. Several serum oncomarkers have been used to determine the prognosis of ILD; however, the prognostic value of serum oncomarker levels in patients with AE-ILD remains unclear.
Objective: To evaluate the prognostic value of serum oncomarker levels in patients with AE-ILD and its main subtypes.
Design: Retrospective study.
Methods: The serum levels of 8 oncomarkers in 281 patients hospitalized with AE-ILD at our institution between 2017 and 2022 were retrospectively reviewed. The baseline characteristics and serum oncomarker levels were compared between the survival and non-survival groups of AE-ILD and its main subtypes. Multivariate logistic regression analysis was performed to identify independent prognosis-related markers, and the best prognostic predictor was analyzed using receiver operating characteristic curve (ROC) analysis.
Result: Idiopathic pulmonary fibrosis (IPF; n = 65), idiopathic nonspecific interstitial pneumonia (iNSIP; n = 26), and connective tissue disease-associated interstitial lung disease (CTD-ILD; n = 161) were the three main subtypes of ILD. The in-hospital mortality rate among patients with AE-ILD was 21%. The serum oncomarker levels of most patients with AE-ILD and its main subtypes in the non-survival group were higher than those in the survival group. Multivariate analysis revealed that ferritin and cytokeratin 19 fragments (CYFRA21-1) were independent prognostic risk factors for patients hospitalized with AE-ILD or AE-CTD-ILD. CYFRA21-1 was identified as an independent prognostic risk factor for patients hospitalized with AE-IPF or AE-iNSIP.
Conclusion: CYFRA21-1 may be a viable biomarker for predicting the prognosis of patients with AE-ILD, regardless of the underlying subtype of ILD. Ferritin has a prognostic value in patients with AE-ILD or AE-CTD-ILD.
Keywords: acute exacerbation; idiopathic pulmonary fibrosis; interstitial lung disease; oncomarker; tumor marker.
Conflict of interest statement
The authors declare that there is no conflict of interest.
Figures



Similar articles
-
The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.PLoS One. 2021 Jul 27;16(7):e0255365. doi: 10.1371/journal.pone.0255365. eCollection 2021. PLoS One. 2021. PMID: 34314462 Free PMC article.
-
Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease.Respir Med. 2021 Sep;186:106534. doi: 10.1016/j.rmed.2021.106534. Epub 2021 Jul 7. Respir Med. 2021. PMID: 34260978
-
Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study.BMC Pulm Med. 2019 Nov 14;19(1):215. doi: 10.1186/s12890-019-0960-1. BMC Pulm Med. 2019. PMID: 31727051 Free PMC article.
-
Relationship between idiopathic interstitial pneumonias (IIPs) and connective tissue disease-related interstitial lung disease (CTD-ILD): A narrative review.Respir Investig. 2024 May;62(3):465-480. doi: 10.1016/j.resinv.2024.03.006. Epub 2024 Apr 1. Respir Investig. 2024. PMID: 38564878 Review.
-
Serum surfactant protein D as a significant biomarker for predicting occurrence, progression, acute exacerbation, and mortality in interstitial lung disease: a systematic review and meta-analysis.Front Immunol. 2025 Feb 14;16:1450798. doi: 10.3389/fimmu.2025.1450798. eCollection 2025. Front Immunol. 2025. PMID: 40028331 Free PMC article.
Cited by
-
Sivelestat sodium: a novel therapeutic agent in a mouse model of acute exacerbation pulmonary fibrosis through multiple mechanisms.J Thorac Dis. 2025 Jul 31;17(7):5024-5043. doi: 10.21037/jtd-2025-163. Epub 2025 Jul 29. J Thorac Dis. 2025. PMID: 40809237 Free PMC article.
-
Dynamics of serum tumor markers may indicate the progression of interstitial lung disease in Sjögren's syndrome patients: new roles for old friends.Clin Exp Med. 2025 Jul 1;25(1):229. doi: 10.1007/s10238-025-01779-9. Clin Exp Med. 2025. PMID: 40591000 Free PMC article.
References
-
- Miyashita K, Kono M, Saito G, et al.. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis. Clin Respir J 2021; 15: 336–344. - PubMed
-
- Moua T, Westerly BD, Dulohery MM, et al.. Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: a large cohort analysis. Chest 2016; 149: 1205–1214. - PubMed
-
- Suzuki A, Kondoh Y, Brown KK, et al.. Acute exacerbations of fibrotic interstitial lung diseases. Respirology 2020; 25: 525–534. - PubMed
-
- Rusanov V, Kramer MR, Raviv Y, et al.. The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation. Chest 2012; 141: 1047–1054. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical